Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide in Alzheimer's Disease
NCT07200622Phase 2Not yet recruiting
- Sponsor
- Imperial College London
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of semaglutide in Alzheimer's disease (AD), sponsored by Imperial College London. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07200622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200622.